|
1
|
Holland EC: Gliomagenesis: Genetic
alterations and mouse models. Nat Rev Genet. 2:120–129. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kleihues P, Louis DN, Scheithauer BW,
Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO
classification of tumors of the nervous system. J Neuropathol Exp
Neurol. 61:215–225. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fukaya R, Ohta S, Yamaguchi M, Fujii H,
Kawakami Y, Kawase T and Toda M: Isolation of cancer stem-like
cells from a side population of a human glioblastoma cell line,
SK-MG-1. Cancer Lett. 28:150–157. 2010. View Article : Google Scholar
|
|
4
|
Hirschmann-Jax C, Foster AE, Wulf GG,
Fujii H, Kawakami Y, Kawase T and Toda M: A distinct ʻside
populationʼ of cells with high drug efflux capacity in human tumor
cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004. View Article : Google Scholar
|
|
5
|
Challen GA and Little MH: A side order of
stem cells: The SP phenotype. Stem Cells. 24:3–12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ramachandran C and Melnick SJ: Multidrug
resistance in human tumors-molecular diagnosis and clinical
significance. Mol Diagn. 4:81–94. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
8
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kondo T, Setoguchi T and Taga T:
Persistence of a small subpopulation of cancer stem-like cells in
the C6 glioma cell line. Proc Natl Acad Sci USA. 101:781–786. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harris MA, Yang H, Low BE, Mukherjee J,
Guha A, Bronson RT, Shultz LD, Israel MA and Yun K: Cancer stem
cells are enriched in the side population cells in a mouse model of
glioma. Cancer Res. 68:10051–10059. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robey RW, Shukla S, Finley EM, Oldham RK,
Barnett D, Ambudkar SV, Fojo T and Bates SE: Inhibition of
P-glycoprotein (ABCB1) and multidrug resistance associated
protein-1 (ABCC1)-mediate transport by the orally administered
inhibitor CBT-1 (R). Biochemical Pharmacol. 75:1302–1312. 2008.
View Article : Google Scholar
|
|
12
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24 (−/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu S, Zhang R, Liu F, Wang H, Wu J and
Wang Y: Notch inhibition suppresses nasopharyngeal carcinoma by
depleting cancer stem like side population cells. Oncol Rep.
28:561–566. 2012.PubMed/NCBI
|
|
14
|
Chearwae W and Bright JJ: PPARγ agonists
inhibit growth and expansion of CD133+ brain tumour stem
cells. Br J Cancer. 99:2044–2053. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo D, Xu BL, Zhang XH and Dong MM: Cancer
stem-like side population cells in the human nasopharyngeal
carcinoma cell line cne-2 possess epithelial mesenchymal transition
properties in association with metastasis. Oncol Rep. 28:241–247.
2012.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side
population is enriched in tumorigenic, stem-like cancer cells,
whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic.
Cancer Res. 65:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ozvegy-Laczka C, Hegedus T, Várady G,
Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K and
Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors
with the ABCG2 multidrug transporter. Mol Pharmacol. 65:1485–1495.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haraguchi N, Utsunomiya T, Inoue H, Tanaka
F, Mimori K, Barnard GF and Mori M: Characterization of a side
population of cancer cells from human gastrointestinal system. Stem
Cells. 24:506–513. 2006. View Article : Google Scholar
|
|
20
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: Cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lino MM, Merlo A and Boulay JL: Notch
signaling in glioblastoma: A developmental drug target? BMC Med.
8:722010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang XP, Zheng G, Zou L, Liu HL, Hou LH,
Zhou P, Yin DD, Zheng QJ, Liang L, Zhang SZ, et al: Notch
activation promotes cell proliferation and the formation of neural
stem cell-like colonies in human glioma cells. Mol Cell Biochem.
307:101–108. 2008. View Article : Google Scholar
|
|
23
|
Fan X, Khaki L, Zhu TS, Soules ME, Talsma
CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, et al: NOTCH pathway
blockade depletes CD133-positive glioblastoma cells and inhibits
growth of tumor neurospheres and xenografts. Stem Cells. 28:5–16.
2010.
|
|
24
|
Sikandar SS, Pate KT, Anderson S, Dizon D,
Edwards RA, Waterman ML and Lipkin SM: NOTCH signaling is required
for formation and self-renewal of tumor-initiating cells and for
repression of secretory cell differentiation in colon cancer.
Cancer Res. 70:1469–1478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhen Y, Zhao S, Li Q, Li Y and Kawamoto K:
Arsenic trioxide-mediated Notch pathway inhibition depletes the
cancer stem-like cell population in gliomas. Cancer Lett.
292:64–72. 2010. View Article : Google Scholar
|
